1. Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases
   Nadire Duru et al, 2022, Proceedings of the National Academy of Sciences CrossRef
2. Genome-Based Classification and Therapy of Prostate Cancer
   Arlou Kristina Angeles et al, 2018, Diagnostics CrossRef
3. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
   Di Cui et al, 2015, Clinical Cancer Research CrossRef
4. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
   Paul Toren et al, 2016, PLOS ONE CrossRef
5. A meta‑analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR‑193a‑5p in lung cancer
   Zu‑Cheng Xie et al, 2018, Oncology Letters CrossRef
6. Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article
   Jason Cham et al, 2021, Clinical Genitourinary Cancer CrossRef
7. Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells
   Antonio J. León-González et al, 2021, Antioxidants CrossRef
8. Enhanced Chemoprevention of Prostate Cancer by Combining Arctigenin with Green Tea and Quercetin in Prostate-Specific Phosphatase and Tensin Homolog Knockout Mice
   Qiongyu Hao et al, 2024, Biomolecules CrossRef
9. Multimodale Therapie des Prostatakarzinoms
   Svenja Dieffenbacher et al, 2018, Aktuelles aus Klinik und Praxis der Urologie CrossRef
10. Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
    Elisabetta Rovida et al, 2015, Seminars in Cancer Biology CrossRef
11. PROSTAGLANDIN E2 stimulates cancer‐related phenotypes in prostate cancer PC3 cells through cyclooxygenase‐2
    Antonio Madrigal‐Martínez et al, 2019, Journal of Cellular Physiology CrossRef
12. Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling
    Gauri Shishodia et al, 2019, The Prostate CrossRef
13. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
    John E. Bisi et al, 2017, Oncotarget CrossRef